mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for MID2
Gene summary
Basic gene Info.Gene symbolMID2
Gene namemidline 2
SynonymsFXY2|MRX101|RNF60|TRIM1
CytomapUCSC genome browser: Xq22.3
Type of geneprotein-coding
RefGenesNM_012216.3,
NM_052817.2,
DescriptionRING finger protein 60midin 2midin-2midline defect 2midline-2probable E3 ubiquitin-protein ligase MID2tripartite motif protein 1tripartite motif-containing protein 1
Modification date20141207
dbXrefs MIM : 300204
HGNC : HGNC
HPRD : 02191
ProteinUniProt: Q9UJV3
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_MID2
BioGPS: 11043
PathwayNCI Pathway Interaction Database: MID2
KEGG: MID2
REACTOME: MID2
Pathway Commons: MID2
ContextiHOP: MID2
ligand binding site mutation search in PubMed: MID2
UCL Cancer Institute: MID2
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0032897negative regulation of viral transcription18248090
GO:0043123positive regulation of I-kappaB kinase/NF-kappaB signaling23077300
GO:0045087innate immune response18248090
GO:0046597negative regulation of viral entry into host cell18248090
GO:1902187negative regulation of viral release from host cell18248090


Top
Ligand binding site mutations for MID2

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
H198H198YSKCM1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for MID2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
H198H198Y-0.70818649
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for MID2 from PDB

Top
Differential gene expression and gene-gene network for MID2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of MID2 and the right PPI network was created from samples without mutations in the LBS of MID2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for MID2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for MID2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of MID2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS


Top
Conservation information for LBS of MID2
Multiple alignments for Q9UJV3 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas